Joshua L. Hood, M.D., Ph.D.

Education:Joshua L. Hood, M.D., Ph.D.

B.S., Biochemistry and Molecular Biology (Major 1), Centre College, Danville, KY; 1999
B.S., Chemistry (Major 2), Centre College, Danville, KY; 1999
Ph.D., Microbiology, University of Kentucky College of Medicine, Lexington, KY; 2004
M.D., Medicine, University of Kentucky College of Medicine, Lexington, KY; 2006
Residency, Clinical Pathology (Laboratory Medicine), Barnes-Jewish Hospital, Department of Pathology
and Immunology, Washington University School of Medicine, St. Louis, MO; 2009
Post-Doc, Nanomedicine, Washington University School of Medicine, Department of Medicine, Consortium for Translational Research in Advanced Imaging and Nanomedicine, St. Louis, MO; 2009

Curriculum Vitae

Current Positions:

Assistant Professor of Pharmacology and Toxicology, Department of Pharmacology and Toxicology
Associate Scientist, James Graham Brown Cancer Center, Experimental Therapeutics Program
Member, Graduate Faculty, University of Louisville School of Medicine

Contact Information:

Kosair Charities Clinical & Translational Research Building
University of Louisville
505 South Hancock Street
Louisville, KY 40202
Phone:  502 852 8411
Fax:  502 852 3661
Email:  Joshua.hood@louisville.edu

Research Description

The study of extracellular vesicles and exosome-based tumor pathogenesis, biomarkers and derivative therapeutics comprise the primary research interests of our laboratory.  Exosomes are naturally occurring biological nanovesicles ~30-150 nm in size.  They are constitutively generated and released into the surrounding extracellular matrix and circulation.  They have been shown to participate in cell-to-cell communication such as receptor and RNA transport between cells.  Tumor exosomes participate in tumor-mediated angiogenesis, immune suppression and growth.

In past investigations we discovered that melanoma exosomes prepare lymph nodes for metastasis by establishing pre-metastatic niches.  We are continuing to build on this finding by investigating the influence of melanoma exosomes on endothelial- and macrophage-mediated tumor supportive inflammatory processes. 

The results of our basic science investigations are being used to guide the development of personalized exosome-based biomarkers through collaborations with our James Graham Brown Cancer Center (JGBCC) colleagues.  Biomarker discovery efforts are supported in part through research into the development of “label free” microfluidic exosome detection, isolation and collection technologies in collaboration with mechanical engineers.  High throughput and high volume microfluidic machines will be used to facilitate the collection and banking of exosome subtypes for biorepositories. 

Such technologies also support the long term translational goals of the lab to design and translate personalized exosome-based therapeutics.  This includes developing means to convert exosomes into biocompatible nanocarriers able to carry a variety of therapeutic payloads to target and treat tumor microenvironments for melanoma, lung cancer, or other cancer types.  Current exosomal therapies being pursued in the lab include lung cancer and melanoma exosome-based immunotherapeutics and tumor exosome vaccines in collaboration with our JGBCC colleagues.

Literature Cited:

  • *Hood JL, Logan BB, Sinai AP, Brooks WH, Roszman TL.  Association of the calpain/calpastatin network with subcellular organelles.  Biochemical and Biophysical Research Communications 2003 Oct 31;310(4):1200-12.  PMID: 14559243.
  • *Hood JL, Brooks WH, Roszman TL.  Differential compartmentalization of the calpain/calpastatin network with the endoplasmic reticulum and Golgi apparatus.  Journal of Biological Chemistry 2004 Oct 8;279(41):43126-35.  PMID: 15302874. [www.jbc.org/content/279/41/43126.long ]
  • *Hood JL, Brooks WH, Roszman TL.  Subcellular mobility of the calpain/calpastatin network – an organelle transient.  Bioessays 2006 Aug;28(8):850-9.  PMID: 16927317.
  • *Hood JL, Eby CS.  Evaluation of a prolonged prothrombin time.  Clinical Chemistry 2008 Apr;54(4):765-9.  PMID: 18375491. [ http://clinchem.aaccjnls.org/content/54/4/765.long ]
  • *Hood JL, Pan H, Lanza GM, Wickline SA.  Paracrine induction of endothelium by tumor exosomes.  Laboratory Investigation 2009 Nov;89(11):1317-28.  PMID: 19786948. PMCID: PMC3316485.
  • Pan H, Myerson JW, Ivashyna O, Soman NR, Marsh JN, Hood JL, Lanza GM, Schlesinger PH, Wickline SA.  Lipid membrane editing with peptide cargo linkers in cells and synthetic nanostructures.  FASEB Journal 2010 Aug;24(8):2928-37.  PMID: 20335225. PMCID: PMC2909291.
  • *Hood JL, San Roman S, Wickline SA.  Exosomes released by melanoma cells prepare sentinel lymph nodes for tumor metastasis.  Cancer Research 2011 Jun 1;71(11):3792–801.  PMID: 21478294.  [ http://cancerres.aacrjournals.org/content/71/11/3792.long ]
  • *Hood JL, Wickline SA.  A systematic approach to exosome based translational nanomedicine.  Wiley Interdisciplinary Reviews in Nanomedicine and Nanobiotechnology 2012 Jul-Aug;4(4):458-67. PMID: 22648975.
  • *Hood JL, Jallouk AP, Campbell N, Ratner L, Wickline SA.  Cytolytic nanoparticles attenuate HIV-1 infectivity. Antiviral Therapy 2012;18(1):95-103.  PMID: 22954649.
  • *Hood JL, Scott MJ, Wickline SA.  Maximizing exosome colloidal stability following electroporation.  Analytical Biochemistry 2014 Mar 1;448:41-9.  PMID: 24333249. PMCID: PMC3954633.
  • Jallouk AP, Moley KH, Omurtag K, Hu G, Lanza GM, Wickline SA, *Hood JL.  Nanoparticle incorporation of melittin reduces sperm and vaginal epithelium cytotoxicity.  PLoS One 2014Apr 18;9(4):e95411.  PMID: 24748389. PMCID: PMC3991669.
  • Petersen KE, Manangon L, Hood JL, Wickline SA, Fernandez DP, Johnson WP, Gale BK.  A review of exosome separation techniques and characterization of B16-F10 mouse melanoma exosomes with AF4-UV-MALS-QELS-DLS-TEM.  Analytical & Bioanalytical Chemistry 2014 Dec;406(30):7855-66.  PMID: 25084738. PMCID: PMC4492512.
  • Hu L, Wickline SA, *Hood JL.  Magnetic resonance imaging of melanoma exosomes in lymph nodes.  Magnetic Resonance in Medicine 2015 Jul;74(1):266-71.  PMID: 25052384. PMCID: PMC4422779.
  • *Hood JL.  Melanoma exosomes enable tumor tolerance in lymph nodes. Medical Hypotheses 2016 May;90:11-13.  PMID: 27063077.  PMCID: PMC4829918.
  • *Hood JL.  Post isolation modification of exosomes for nanomedicine applications. Nanomedicine (London) 2016 Jul;11(13):1745-56.  PMID: 27348448.  PMCID: PMC4941124.
  • *Hood JL.  Melanoma exosome induction of endothelial cell GM-CSF in pre-metastatic lymph nodes may result in different M1 and M2 macrophage mediated angiogenic processes.  Medical Hypotheses 2016 Sep;94:118-22.  PMID: 27515216.  PMCID: PMC4988397.
  • *Hood JL.  The association of exosomes with lymph nodes. Seminars in Cell & Developmental
  • Biology 2017 Jul;67:29-38.  Review. PMID: 27916565.
  • Bardi GT, Smith MA, *Hood JL.  Melanoma exosomes promote mixed M1 and M2 macrophage polarization.  Cytokine 2018 May;105:63-72.  PMID: 29459345.  [ https://www.sciencedirect.com/science/article/pii/S1043466618300425?via%3Dihub
* = first/corresponding/senior author

PubMed Information